Lancet. 2011 Dec 17;378(9809):2056-7. doi: 10.1016/S0140-6736(11)61254-3. Epub 2011 Nov 3.

High-risk prostate cancer: treat the prostate.

Cooperberg MR.

Source

Department of Urology, University of California, San Francisco, CA 94143, USA. mcooperberg@urology.ucsf.edu

Comment on

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. [Lancet. 2011]
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, et al. Lancet. 2011 Dec 17; 378(9809):2104-11. Epub 2011 Nov 2.

PMID:: 22056154; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Comment

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Prostate Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Hormonal management of advanced adenocarcinoma of the prostate. [Henry Ford Hosp Med J. 1989]
Hormonal management of advanced adenocarcinoma of the prostate.
Miles BJ. Henry Ford Hosp Med J. 1989; 37(1):16-8.
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). [Cancer. 2006]
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. Cancer. 2006 Apr 15; 106(8):1708-14.
Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. [J Urol. 2007]
Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. J Urol. 2007 Apr; 177(4):1307-12.
Review What to do if prostate cancer returns. [Johns Hopkins Med Lett Health ...]
Review What to do if prostate cancer returns.
[No authors listed]Johns Hopkins Med Lett Health After 50. 2001 Dec; 13(10):6-7.
Review Combined androgen blockade. [Urology. 1989]
Review Combined androgen blockade.
Crawford ED. Urology. 1989 Oct; 34(4 Suppl):22-6; discussion 46-56.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

High-risk prostate cancer: treat the prostate.
High-risk prostate cancer: treat the prostate.
Lancet. 2011 Dec 17 ;378(9809):2056-7. doi: 10.1016/S0140-6736(11)61254-3. Epub 2011 Nov 3 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: